cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2012-5-67-70cardiovascular-1921Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMРоль ангиопротекции в лечении артериальной гипертензии: фокус на олмесартанAngioprotection role in arterial hypertension treatment: focus on olmesartanНебиеридзеД. В.NebieridzeD. V.dneberidze@gnicpm.ruСафарянА. С.SafaryanA. S.dneberidze@gnicpm.ruИванишинаТ. В.IvanishinaT. V.dneberidze@gnicpm.ruВинницкаяН. Л.VinnitskayaN. L.dneberidze@gnicpm.ruФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрасоцразвития России, МоскваState Research Centre for Preventive Medicine, Moscow2012201020121156770Copyright © Небиеридзе Д.В., Сафарян А.С., Иванишина Т.В., Винницкая Н.Л., 20122012Небиеридзе Д.В., Сафарян А.С., Иванишина Т.В., Винницкая Н.Л.Nebieridze D.V., Safaryan A.S., Ivanishina T.V., Vinnitskaya N.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1921

В статье отражено значение органопротекции при лечении артериальной гипертонии. Представлен обзор международных исследований, касающихся эффективности современного представителя блокаторов рецепторов ангиотензина II – олмесартана. Результаты этих исследований свидетельствуют не только о выраженном антигипертензивном эффекте олмесартана, но и о его вазопротекторных свойствах: уменьшает сосудистое воспаление, вызывает регресс гипертрофированной сосудистой стенки, сокращает объем атеросклеротической бляшки. В России сравнительно недавно появился препарат Кардосал®. Благодаря солидной доказательной базе, как в плане антигипертензивного эффекта, так и в плане ангиопротекции у этого препарата хорошие перспективы применения для лечения различных категорий пациентов. При этом можно рассчитывать не только на адекватный контроль артериального давления, но и на эффективное снижение риска осложнений.

The paper discusses the role of organoprotection in arterial hypertension treatment. The results of international studies on effectiveness of olmesartan, a modern angiotensin II receptor antagonist, are presented. The available evidence confirms not only a strong antihypertensive effect of olmesartan, but also its vasoprotective characteristics. Olmesartan reduces vascular inflammation, facilitates the regression of vascular wall hypertrophy, and reduces the volume of atherosclerotic plaque. In Russia, the medication Cardosal® has become available relatively recently. Due to the extensive evidence base confirming its antihypertensive and vasoprotective effects, this medication appears promising for various clinical groups of Russian hypertensives. Not only adequate blood pressure control, but also effective reduction in the risk of cardiovascular complications could be expected.

олмесартандисфункция эндотелияангиопротекциямикроальбуминурияблокаторы рецепторов ангиотензина IIolmesartanendothelial dysfunctionangioprotectionmicroalbuminuriaangiotensin II receptor antagonistsReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5-26. Russian (Detection and treatment of arterial hypertension, Russian guidelines (4th revision). Systemic hypertension 2010; 3: 5-26).Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 5-26. Russian (Detection and treatment of arterial hypertension, Russian guidelines (4th revision). Systemic hypertension 2010; 3: 5-26).Dzau VJ, Braun-Dullaeus R, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nature Medicine 2002; 8(11): 1249-56.Dzau VJ, Braun-Dullaeus R, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nature Medicine 2002; 8(11): 1249-56.Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11(6): RA194-205.Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11(6): RA194-205.Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98(1): 121-8.Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98(1): 121-8.Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23(1): S9-17.Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23(1): S9-17.Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90(4): 449-55.Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90(4): 449-55.Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21(1): 20-7.Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21(1): 20-7.Turnbull, F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527-35.Turnbull, F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527-35.Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3(5): 283-91, 318.Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3(5): 283-91, 318.Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23(7): 419-30.Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23(7): 419-30.Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5(1): 41-50.Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5(1): 41-50.Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Circulation 2004; 110(9):1103-7. Epub 2004 Aug 16.Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Circulation 2004; 110(9):1103-7. Epub 2004 Aug 16.Smith RD, Yokoyama H, Averi ll DB, et al. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Society Hypertens 2008; 2 (3): 165-72.Smith RD, Yokoyama H, Averi ll DB, et al. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Society Hypertens 2008; 2 (3): 165-72.Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therap Adv Cardiovasc Dis 2007; 1(2): 97-106.Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therap Adv Cardiovasc Dis 2007; 1(2): 97-106.Hermann Haller, Sadayoshi Ito, Joseph L, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. N Engl J Med 2011; 364:907-917. March 10, 2011.Hermann Haller, Sadayoshi Ito, Joseph L, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. N Engl J Med 2011; 364:907-917. March 10, 2011.

The authors declare that there are no conflicts of interest present.